Champions Oncology, Inc. CSBR
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.84% | 11.98% | -2.82% | 11.46% | -0.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.84% | 11.98% | -2.82% | 11.46% | -0.47% |
| Cost of Revenue | -5.77% | -6.34% | 33.50% | -2.23% | 13.05% |
| Gross Profit | 28.30% | 38.18% | -25.88% | 28.25% | -14.15% |
| SG&A Expenses | 30.24% | 12.33% | 34.18% | 36.59% | 5.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.85% | 2.04% | 33.54% | 16.41% | 13.90% |
| Operating Income | 19.33% | 69.60% | -104.16% | -74.73% | -138.15% |
| Income Before Tax | 8.19% | 74.80% | -105.25% | -65.49% | -133.88% |
| Income Tax Expenses | -21.43% | 233.33% | 82.61% | 63.64% | -33.33% |
| Earnings from Continuing Operations | 8.58% | 63.65% | -106.21% | -67.45% | -135.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.58% | 63.65% | -106.21% | -63.19% | -135.49% |
| EBIT | 19.33% | 69.60% | -104.16% | -74.73% | -138.15% |
| EBITDA | 36.24% | 84.85% | -96.86% | -52.08% | -108.38% |
| EPS Basic | 9.17% | 64.09% | -106.13% | -63.81% | -134.99% |
| Normalized Basic EPS | 4.59% | 70.75% | -103.25% | -59.41% | -131.97% |
| EPS Diluted | 9.17% | 64.09% | -106.48% | -61.20% | -137.56% |
| Normalized Diluted EPS | 4.59% | 70.75% | -103.41% | -60.00% | -133.00% |
| Average Basic Shares Outstanding | 0.79% | 1.16% | 1.36% | 1.46% | 1.43% |
| Average Diluted Shares Outstanding | 0.79% | 1.16% | -3.33% | 3.14% | -1.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |